JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Sponsor
Boehringer Ingelheim
Study ID
NCT06287073
Status
Completed

Conditions

  • Kidney Disease, Chronic

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JARDIANCE® — DRUG
    JARDIANCE®

Study Details

The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.

Key Dates

Start date
Mar 29, 2024
Status verified
May 2026
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
299 participants (actual)

Arms

  • Arm: JARDIANCE® treated patients
    Patients with chronic kidney disease (CKD) who started JARDIANCE® for the first time in accordance with the approved label in Korea, treated according to routine clinical practice.

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 337 days. ]

Related coverage on Hipa.ai

Related Studies